MedTrace Logo

Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria

NCT00425763 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2012-04-05

No results posted yet for this study

Summary

We will be studying the clinical efficacy of amodiaquine-artesunate currently being studied in an intermittent preventive therapy in infants (IPTi)trial in the same area in order to correlate preventive efficacy seen in IPTi with efficacy for treatment of symptomatic malaria for each regimen.

Conditions

Interventions

DRUG

AQAS

AQAS dosed by body weight, on days 0, 1, 2

Sponsors & Collaborators

Principal Investigators

  • Meghna Desai, PhD · Centers for Disease Control and Prevention

  • Mary Hamel, MD · Centers for Disease Control and Prevention

  • Patrick Kachur, MD, MPH · Centers for Disease Control and Prevention

  • Robert Newman, MD, MPH · Centers for Disease Control and Prevention

  • Larry Slutsker, MD, MPH · Centers for Disease Control and Prevention

  • Julie Thwing, MD · Centers for Disease Control and Prevention

  • Christopher O Odero · CDC/KEMRI

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Kenya

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425763 on ClinicalTrials.gov